In-lab footage of two scientists working at Gilead.


Focused on

A new model for collaboration and partnership.

Disruption by Collaboration

Linda Higgins, Senior Vice President of External Innovation at Gilead, explains our collaborative approach to research and development.

A Venn diagram.

Two Companies.
One Goal.

With our transformative partnership, Gilead and Galapagos are expanding and accelerating our research and commercialization programs to support unmet medical needs.

Addressing Unmet
Medical Needs

A Pipeline of Possibilities

To us, the impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next, integrating internal and external research to build a robust pipeline.

Taking It to the Next Level

Through the years, Gilead’s research programs have helped propel science forward. Now, with the creation of our External Innovation Center, we’re working more closely with partners to bring the best learnings to our teams as we aim to bring 10+ new transformative therapies to patients in the next 10 years. In 2019, we established more than 17 strategic partnerships and licensing deals to keep the momentum going.

Various teams collaborating on Gilead's main campus in Foster City, California

"Together with our industry’s most-respected colleagues, Gilead is pushing the limits of its R&D capabilities, putting patients and their quality of life front and center."

Linda Higgins, SVP of External Innovation at Gilead

A close-up of a microscope

We're Ready for What's Next

The work is already underway. Read Gilead’s 2019 Year in Review to learn more.